H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma (ABUS) on January 26 and set a price target of $10.00. The company’s shares closed last Tuesday at $3.60.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 16.2% and a 41.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Arbutus Biopharma is a Moderate Buy with an average price target of $6.43, which is a 90.2% upside from current levels. In a report issued on January 14, Chardan Capital also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Arbutus Biopharma’s market cap is currently $348.3M and has a P/E ratio of -3.30. The company has a Price to Book ratio of -6.73.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
